"Two global trends are on a collision course to upend decades of medical progress and health outcomes: antimicrobial resistance, or AMR, and our rapidly aging society."
healthaffairs.org
healthaffairs.org
"The current trajectory for AMR is bleak: AMR pathogens are estimated to kill 700,000..each year, and the UN forecasts..AMR could kill up to 10 million..annually by 2050 and push 24 million..into poverty by 2030. Meanwhile, our antibiotic innovation pipeline is bare"
"[A]ntibiotics have added an estimated average of 20 years to the human lifespan, but if the incidence of multidrug resistant pathogens continues to increase, the drugs that have unlocked this longevity miracle will no longer be effective."
"[W]e..need new drugsβinnovation is not working. Right now, there are no clear incentives to take on the high costs of developing these drugs, which would need to be held in reserve rather than sold and used at scale."
"Consider that in the United Kingdom only one new antibiotic was approved in the 15 years between 1999 and 2014, and fewer than 150 researchers are working on the problem in the industry, predominantly in small-to-medium-size biotech companies."
"The antibiotic revolution barely a century ago inspired and fueled the miracle of longevity that the 20th century bequeathed to our current era. Now, we need antibiotic innovation to not only continue the drive for longevity but also extend it to create healthy..longevity."
Loading suggestions...